secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptive Biotechnologies Corp (ADPT)
CIK:        0001478320
Form:       8-K
Filed at:   2022-06-14T23:59:59+00:00
Accession:  0001564590-22-023130
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Adaptive Biotech shareholders elect three Class III directors, approve advisory compensation, ratify auditor
--------------------------------------------------------------------------------

- Chad Robins, Kevin Conroy, Michael Pellini elected as Class III directors to 2025 term.
- Advisory vote on 2021 NEO compensation approved: 72.7M for, 44.5M against, 298k abstentions.
- Ernst & Young ratified as independent auditor for FY2022: 129.8M for, 55k against, 71k abstentions.
- All proposals passed at June 10, 2022 annual meeting; no broker non-votes for auditor ratification.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1478320/000156459022023130/0001564590-22-023130-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1478320/000156459022023130/adpt-8k_20220610.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-023130

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer